Biofidelity

Biofidelity is a pioneer in the field of molecular diagnostics, with a mission to unlock the benefits of precision medicine for all patients by increasing opportunities for early detection, accurate diagnosis, and routine monitoring through its revolutionary technology. Founded in 2019, Biofidelity initially focused on the diagnosis of non-small cell lung cancer, with broad potential applications across various cancers as well as in detecting drug resistance and disease recurrence. Biofidelity’s disruptive technology combines rapid, affordable, and easy-to-interpret results, greatly simplifying genetic testing while delivering all the key advantages of next-generation sequencing (NGS).